An analysis of the large global DELIVER trial found that dapagliflozin improved outcomes and symptoms across a wide range of patients with heart failure.
People with type 2 diabetes who tried agents from three different classes of glucose-lowering drugs usually found one they liked most. It was also often their safest and most effective option.
Thailand: A recent study published in Cardiovascular Diabetology has compared the treatment effectiveness of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on renal outcomes with other second-line.
In patients with type 2 diabetes and peripheral artery disease who undergo revascularization, cardiovascular and renal benefits of the agents were confirmed without increased risk of limb amputation.